You are here » Home » Companies » Company Overview » Astrazeneca Pharma India Ltd

Astrazeneca Pharma India Ltd.

BSE: 506820 Sector: Health care
NSE: ASTRAZEN ISIN Code: INE203A01020
BSE 00:00 | 01 Dec 3327.65 -52.20
(-1.54%)
OPEN

3329.55

HIGH

3384.60

LOW

3317.50

NSE 00:00 | 01 Dec 3329.75 -44.05
(-1.31%)
OPEN

3370.90

HIGH

3381.40

LOW

3320.00

OPEN 3329.55
PREVIOUS CLOSE 3379.85
VOLUME 1189
52-Week high 3619.70
52-Week low 2437.75
P/E 90.30
Mkt Cap.(Rs cr) 8,319
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 3329.55
CLOSE 3379.85
VOLUME 1189
52-Week high 3619.70
52-Week low 2437.75
P/E 90.30
Mkt Cap.(Rs cr) 8,319
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Astrazeneca Pharma India Ltd. (ASTRAZEN) - Chairman Speech

Company chairman speech

Doing The Right Thing The Right Way!

Dear Shareholder

I hope that you and your family are in good health.

The pandemic has severely impacted the economy in more than 216 countries includingIndia. In light of this global challenge the pharmaceutical industry has expanded itsresearch into COVID-19 at an unprecedented pace.

AstraZeneca's core values focus on following the science putting patients first anddoing the right thing. When AstraZeneca PLC UK partnered with the University of Oxford inthe landmark journey these values were in focus. This helped stitch together thepartnership in record time as its values matched and they committed to ensuring that theywould access as many patients across the world as possible. The company* was clear fromthe start that this was not for profit and was for equitable access. A number of alliancesalso worked for this - Coalition for Epidemic Preparedness GAVI etc. and were supportedby foundations like Gates Foundation. These partnerships ensure that the delivery of thevaccine started across the world especially in low-income regions like West Africa.Partnerships with Serum Institute in India and similar ones in Korea Brazil Russia andothers were established to ensure that there are enough vaccines. Thus trialspartnerships with producers agreements with governments all took place simultaneously.The company quickly supplied vaccines to 130 countries and 400 million doses had beenadministered by early June. This was the most by any vaccine producer.

We achieved remarkable pipeline and regulatory performances in 2020 with 10 approvalsof new medicines or life-cycle management indications in major markets. Despite theoccasional setback considering the situation we were able to secure 3 major approvalswith Dapa-HF and Dapa CKD in CVRM FASENRA in Severe Asthma Tagrisso ADAURA (for adjuvanttreatment after complete tumour resection in patients with NSCLC whose tumours have EGFRmutations) and Calquence for CLL. With this we created the next wave of our innovativepipeline ensuring the sustainable delivery of new products. We have been able to get 17clinical trial application approvals in India; thereby bringing in novel therapeuticoptions in a clinical setting for patients with an unmet need.

At such a time digital technologies play an important role.

We were successful in identifying the gap in patient-healthcare professional (HCP)connect and developed tangible solutions. Activation of Virtual Patient Care ManagementServices as part of beyond-the-pill solution supported with EMR and Telemedicine Servicesenabled better connect between HCPs and patients during the period of restricted access tophysical clinics. We also initiated patient education campaigns via our e-Pharma partnersacross social media channels. We invested in a stronger digital ecosystem that enabledvirtual connects between our representatives and HCPs online consultations for patientsand timely delivery of life-saving drugs at the patient's doorstep.

(*The company here refers to AstraZeneca PLC UK)

Additionally we sought to reduce the impact of the pandemic on cancer outcomes by forexample launching ‘New Normal Same Cancer' campaign which we co-created with sevenleading global patient coalitions to encourage patients whose care had been interruptedto re-engage with the healthcare system.

There is now a higher focus on automation digitisation as well as increased dependenceon analytical tools for decisionmaking. We are leveraging IT technology tools to ensurebusiness continuity as well as to facilitate work from home (WFH) for many functions inthe organisation. Changes at our manufacturing facilities have been implemented to boostproductivity as well as ensure adherence to all safety and hygiene protocols.

(#IPSOS June 2020 Dataset; Oncology entire market considered)

Our performance in 2020-21 marked a significant step forward for AstraZeneca. Theconsistent achievements in the pipeline accelerating performance of our business theextraordinary commitment of our people and continued supply of our medicines played animportant role in fuelling our overarching objective of ‘No patients left behind'. Weare the fastest growing company in Oncology at 150% and 3rd biggest Oncology brand inIndia.#

I am grateful to our Board of Directors for their guidance and support in theseuncertain times. We are also thankful for your support as a shareholder and we hope thatyou will continue to repose your confidence in us in the future as well.

Gagandeep Singh

MD AstraZeneca Pharma India Limited

.